MicroRNA‑146a regulates the transformation from liver fibrosis to cirrhosis in patients with hepatitis B via interleukin‑6

Yang,Zhaohui; Peng,Yulong; Yang,Suxian

doi:10.3892/etm.2019.7490

MicroRNA‑146a regulates the transformation from liver fibrosis to cirrhosis in patients with hepatitis B via interleukin‑6

Authors:
- Zhaohui Yang
- Yulong Peng
- Suxian Yang
View Affiliations

Affiliations: Department of Infection, Linyi People's Hospital, Linyi, Shandong 276003, P.R. China
Published online on: April 16, 2019 https://doi.org/10.3892/etm.2019.7490
Pages: 4670-4676

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to measure the expression of microRNA (miR)‑146a in liver tissues, peripheral blood mononuclear cells (PMBC) and serum from patients with Hepatitis B and either liver fibrosis or cirrhosis, as well as to determine the regulatory mechanism of miR‑146a. A total of 36 patients with Hepatitis B and liver fibrosis and 25 patients with hepatitis B and liver cirrhosis admitted to Linyi People's Hospital (Shandong, China) between June 2012 and February 2016 were included in the present study. Reverse transcription‑quantitative polymerase chain reaction was performed to determine the expression of miR‑146a and interleukin (IL)‑6 mRNA in the liver tissue, PBMCs and serum. Western blotting was used to assess the expression of IL‑6 in liver tissues and PBMCs. An enzyme‑linked immunosorbent assay was conducted to measure IL‑6 levels in serum. To identify the direct interaction between IL‑6 and miR‑146a, a dual luciferase reporter assay was performed. IL‑6 mRNA expression in liver tissues, PBMCs and serum from patients with liver cirrhosis was significantly higher than that from patients with liver fibrosis (P<0.05). Furthermore, IL‑6 expression in liver tissues and PBMCs from patients with liver cirrhosis was enhanced and levels of IL‑6 protein in the serum of patients with liver cirrhosis were significantly elevated compared with patients with liver fibrosis (P<0.05). By contrast, levels of miR‑146a in liver tissues, PBMCs and serum from patients with liver cirrhosis were significantly downregulated (P<0.05) compared with patients with liver fibrosis. miR‑146a regulated the expression of IL‑6 by binding to its 3'‑untranslated region. Thus, in the transformation from liver fibrosis to cirrhosis, the upregulation of IL‑6 in liver tissues, PBMCs and serum may be associated with the downregulation of miR‑146a. miR‑146a directly targets IL‑6, which may regulate the occurrence and immune responses of Hepatitis B.

View Figures

View References

1	Cabre A, Babio N, Lazaro I, Lázaro I, Bulló M, Garcia-Arellano A, Masana L and Salas-Salvadó J: FABP4 predicts atherogenic dyslipidemia development. The PREDIMED study. Atherosclerosis. 222:229–234. 2012. View Article : Google Scholar : PubMed/NCBI
2	Tawada A, Kanda T, Imazeki F and Yokosuka O: Prevention of Hepatitis B virus-associated liver diseases by antiviral therapy. Hepatol Int. 10:574–593. 2016. View Article : Google Scholar : PubMed/NCBI
3	de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A, Paumgartner G, Pietrangelo A, Rodés J, et al: EASL international consensus conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol. 39 (Suppl 1):S3–S25. 2003.PubMed/NCBI
4	Chen YC, Chu CM, Yeh CT and Liaw YF: Natural course following the onset of cirrhosis in patients with chronic Hepatitis B: A long-term follow-up study. Hepatol Int. 1:267–273. 2007. View Article : Google Scholar : PubMed/NCBI
5	Chu CM and Liaw YF: Hepatitis B virus-related cirrhosis: Natural history and treatment. Semin Liver Dis. 26:142–152. 2006. View Article : Google Scholar : PubMed/NCBI
6	Bataller R and Brenner DA: Liver fibrosis. J Clin Invest. 115:209–218. 2005. View Article : Google Scholar : PubMed/NCBI
7	Pinzani M: Liver fibrosis. Springer Semin Immunopathol. 21:475–490. 1999. View Article : Google Scholar : PubMed/NCBI
8	Safadi R and Friedman SL: Hepatic fibrosis-role of hepatic stellate cell activation. MedGenMed. 4:272002.PubMed/NCBI
9	Trepo C, Chan HL and Lok A: Hepatitis B virus infection. Lancet. 384:2053–2063. 2014. View Article : Google Scholar : PubMed/NCBI
10	Sun M and Kisseleva T: Reversibility of liver fibrosis. Clin Res Hepatol Gastroenterol. 39 (Suppl 1):S60–S63. 2015. View Article : Google Scholar : PubMed/NCBI
11	Calvaruso V and Craxi A: Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? Liver Int. 34 (Suppl 1):S85–S90. 2014. View Article : Google Scholar
12	Jiang XI, Luo Y, Zhao S, Chen Q, Jiang C, Dai Y, Chen Y and Cao Z: Clinical significance and expression of microRNA in diabetic patients with erectile dysfunction. Exp Ther Med. 10:213–218. 2015. View Article : Google Scholar : PubMed/NCBI
13	Jia W, Wu Y, Zhang Q, Gao GE, Zhang C and Xiang Y: Expression profile of circulating microRNAs as a promising fingerprint for cervical cancer diagnosis and monitoring. Mol Clin Oncol. 3:851–858. 2015. View Article : Google Scholar : PubMed/NCBI
14	Graziano A, Lo Monte G, Piva I, Caserta D, Karner M, Engl B and Marci R: Diagnostic findings in adenomyosis: A pictorial review on the major concerns. Eur Rev Med Pharmacol Sci. 19:1146–1154. 2015.PubMed/NCBI
15	Hayes CN and Chayama K: MicroRNAs as biomarkers for liver disease and hepatocellular carcinoma. Int J Mol Sci. 17:2802016. View Article : Google Scholar : PubMed/NCBI
16	Ichikawa Y, Joshita S, Umemura T, Shobugawa Y, Usami Y, Shibata S, Yamazaki T, Fujimori N, Komatsu M, Matsumoto A and Tanaka E: Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Hepatol Res. 47:226–233. 2017. View Article : Google Scholar : PubMed/NCBI
17	Liu Y, Cheng LS, Wu SD, Wang SQ, Li L, She WM, Li J, Wang JY and Jiang W: IL-10-producing regulatory B-cells suppressed effector T-cells but enhanced regulatory T-cells in chronic HBV infection. Clin Sci (Lond). 130:907–919. 2016. View Article : Google Scholar : PubMed/NCBI
18	MacParland SA, Ma XZ, Chen L, Khattar R, Cherepanov V, Selzner M, Feld JJ, Selzner N and McGilvray ID: Lipopolysaccharide and tumor necrosis factor alpha inhibit interferon signaling in hepatocytes by increasing ubiquitin-like protease 18 (USP18) expression. J Virol. 90:5549–5560. 2016. View Article : Google Scholar : PubMed/NCBI
19	Chang TS, Chen CL, Wu YC, Liu JJ, Kuo YC, Lee KF, Lin SY, Lin SE, Tung SY, Kuo LM, et al: Inflammation promotes expression of stemness-related properties in HBV-related hepatocellular carcinoma. PLoS One. 11:e01498972016. View Article : Google Scholar : PubMed/NCBI
20	Li C, Deng M, Hu J, Li X, Chen L, Ju Y, Hao J and Meng S: Chronic inflammation contributes to the development of hepatocellular carcinoma by decreasing miR-122 levels. Oncotarget. 7:17021–17034. 2016.PubMed/NCBI
21	Chang L, Lan T, Wu L, Li C, Yuan Y and Liu Z: The association between three IL-6 polymorphisms and HBV-related liver diseases: A meta-analysis. Int J Clin Exp Med. 8:17036–17045. 2015.PubMed/NCBI
22	Lan T, Chang L, Wu L and Yuan YF: IL-6 plays a crucial role in HBV infection. J Clin Transl Hepatol. 3:271–276. 2015. View Article : Google Scholar : PubMed/NCBI
23	Chinese Society of Hepatology, Chinese Medical Association: Chinese Society of Infectious Diseases, Chinese Medical Association, . The guidelines of prevention and treatment for chronic Hepatitis B. Zhonghua Gan Zang Bing Za Zhi. 13:881–891. 2005.(In Chinese). PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Badding MA, Schwegler-Berry D, Park JH, Fix NR, Cummings KJ and Leonard SS: Sintered indium-tin oxide particles induce pro-inflammatory responses in vitro, in part through inflammasome activation. PLoS One. 10:e01243682015. View Article : Google Scholar : PubMed/NCBI
26	Hunter CA and Jones SA: IL-6 as a keystone cytokine in health and disease. Nat Immunol. 16:448–457. 2015. View Article : Google Scholar : PubMed/NCBI
27	Tanaka T, Narazaki M and Kishimoto T: IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 6:a0162952014. View Article : Google Scholar : PubMed/NCBI
28	Baeuerle PA and Henkel T: Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 12:141–179. 1994. View Article : Google Scholar : PubMed/NCBI
29	Tone M, Powell MJ, Tone Y, Thompson SA and Waldmann H: IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J Immunol. 165:286–291. 2000. View Article : Google Scholar : PubMed/NCBI
30	Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M and Yao Y: Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 141:125–139. 2014. View Article : Google Scholar : PubMed/NCBI
31	Luo Q, Ma X, Wahl SM, Bieker JJ, Crossley M and Montaner LJ: Activation and repression of interleukin-12 p40 transcription by erythroid Kruppel-like factor in macrophages. J Biol Chem. 279:18451–18456. 2004. View Article : Google Scholar : PubMed/NCBI
32	Aarstad HH, Vintermyr OK, Ulvestad E, Kross K, Heimdal JH and Aarstad HJ: In vitro-stimulated IL-6 monocyte secretion and in vivo peripheral blood T lymphocyte activation uniquely predicted 15-year survival in patients with head and neck squamous cell carcinoma. PLoS One. 10:e01297242015. View Article : Google Scholar : PubMed/NCBI
33	Varshney J and Subramanian S: MicroRNAs as potential target in human bone and soft tissue sarcoma therapeutics. Front Mol Biosci. 2:312015. View Article : Google Scholar : PubMed/NCBI
34	Liz J and Esteller M: lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta. 1859:169–176. 2016. View Article : Google Scholar : PubMed/NCBI
35	Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH and Chan EK: Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 10:R1012008. View Article : Google Scholar : PubMed/NCBI
36	Abou-Zeid A, Saad M and Soliman E: MicroRNA 146a expression in rheumatoid arthritis: Association with tumor necrosis factor-alpha and disease activity. Genet Test Mol Biomarkers. 15:807–812. 2011. View Article : Google Scholar : PubMed/NCBI
37	Yamasaki K, Nakasa T, Miyaki S, Yamasaki T, Yasunaga Y and Ochi M: Angiogenic microRNA-210 is present in cells surrounding osteonecrosis. J Orthop Res. 30:1263–1270. 2012. View Article : Google Scholar : PubMed/NCBI
38	Li X, Gibson G, Kim JS, Kroin J, Xu S, van Wijnen AJ and Im HJ: MicroRNA-146a is linked to pain-related pathophysiology of osteoarthritis. Gene. 480:34–41. 2011. View Article : Google Scholar : PubMed/NCBI
39	Li X, Kroin JS, Kc R, Gibson G, Chen D, Corbett GT, Pahan K, Fayyaz S, Kim JS, van Wijnen AJ, et al: Altered spinal microRNA-146a and the microRNA-183 cluster contribute to osteoarthritic pain in knee joints. J Bone Miner Res. 28:2512–2522. 2013. View Article : Google Scholar : PubMed/NCBI
40	Curtale G, Citarella F, Carissimi C, Goldoni M, Carucci N, Fulci V, Franceschini D, Meloni F, Barnaba V and Macino G: An emerging player in the adaptive immune response: MicroRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes. Blood. 115:265–273. 2010. View Article : Google Scholar : PubMed/NCBI
41	Taganov KD, Boldin MP, Chang KJ and Baltimore D: NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA. 103:12481–12486. 2006. View Article : Google Scholar : PubMed/NCBI
42	Larner-Svensson HM, Williams AE, Tsitsiou E, Perry MM, Jiang X, Chung KF and Lindsay MA: Pharmacological studies of the mechanism and function of interleukin-1beta-induced miRNA-146a expression in primary human airway smooth muscle. Respir Res. 11:682010. View Article : Google Scholar : PubMed/NCBI